selective TGFβR1 kinase inhibitor
completed oral CV studies in higher species
from data mining of internal matter and opt.
ACS Med. Chem. Lett. 11, 172-178
Bristol-Myers Squibb, Princeton, NJ
BMS-986260
BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)